Development and Validation of a Sensitive LC-MS/MS Method for the Determination of N-Nitroso-Atenolol in Atenolol-Based Pharmaceuticals
Open Access
- 12 May 2025
- journal article
- research article
- Published by MDPI AG in Separations
- Vol. 12 (5) , 122
Abstract
The recent detection of N-nitroso-atenolol, a mutagenic and potentially carcinogenic impurity in atenolol-based pharmaceuticals, has raised serious safety concerns and emphasized the need for stringent analytical control. This study developed and validated a highly sensitive LC-MS/MS method for quantifying N-nitroso-atenolol in both active pharmaceutical ingredients (APIs) and finished products. Quantification was carried out using multiple reaction monitoring (MRM) under positive-mode electrospray ionization (ESI). Separation was performed on a C18 reversed-phase column with a gradient of water and methanol containing 0.1% formic acid. The method was validated to meet a specification limit of 15 ng/mg, with a linear range of 0.5–80 ng/mL, effectively covering 10–400% of the regulatory threshold. The method exhibited an excellent performance in terms of specificity, accuracy, precision, linearity, and robustness. It achieved a limit of detection (LOD) of 0.2 ng/mL (0.30 ng/mg) and a limit of quantification (LOQ) of 0.5 ng/mL (0.75 ng/mg), alongside a comprehensive uncertainty analysis with an expanded uncertainty of ±3.86 mg/kg. Application to commercial atenolol products confirmed the reliability and practical utility of the method. This validated approach offers a critical tool for pharmaceutical manufacturers and regulatory agencies to monitor and control N-nitroso-atenolol, ensuring compliance and enhancing patient safety.Keywords
This publication has 21 references indexed in Scilit:
- Quantitative Investigation of Nitrosamine Drug Substance‐Related Impurities (NDSRIs) Under Artificial Gastric Conditions by Liquid Chromatography–Tandem Mass Spectrometry and Structure–Activity Relationship AnalysisDrug Testing and Analysis, 2025
- A comprehensive approach for N-nitrosamine determination in pharmaceuticals using a novel HILIC-based solid phase extraction and LC-HRMSTalanta, 2024
- Simultaneous determination of low molecular weight nitrosamines in pharmaceutical products by fast gas chromatography mass spectrometryJournal of Chromatography A, 2023
- Nitrosated Active Pharmaceutical Ingredients – Lessons Learned?Journal of Pharmaceutical Sciences, 2023
- The Landscape of Potential Small and Drug Substance Related Nitrosamines in PharmaceuticalsJournal of Pharmaceutical Sciences, 2022
- Analysis of genotoxic N-nitrosamines in active pharmaceutical ingredients and market authorized products in low abundance by means of liquid chromatography – tandem mass spectrometryJournal of Pharmaceutical and Biomedical Analysis, 2022
- A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug ProductsJournal of Pharmaceutical Sciences, 2022
- Nitrosamine Contamination in Pharmaceuticals: Threat, Impact, and ControlJournal of Pharmaceutical Sciences, 2021
- EMA recommendations on nitrosamine impurities in sartansReactions Weekly, 2020
- The contamination of valsartan and other sartans, part 1: New findingsJournal of Pharmaceutical and Biomedical Analysis, 2019